In 301 statin-treated adults with prior ASCVD or increased risk, oral PCSK9 inhibitor enlicitide lowered LDL-C by 64.6% at day 56 vs 6.3% (bempedoic acid), 27.8% (ezetimibe) and 36.5% (both); superior to each (P<0.001), with similar adverse events.
RCTn = 301
Catapano et al. Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial